Clinical experience with brinase.

Clinical Experience with Aureomycin.

Clinical Experience with Surital Sodium*

StrmWAL sodium was introduced to the Canadian market this year as a proven intravenous anaesthetic agent. For thls reaso-ff~it was f~lt timely to discuss the place of Surital m present day clinical anaesthesia. It is gratifying to note that Surital has had a long and careful laboratory and clinical trial, over a period of seven years, before it was released to the open market. There have been f...

Clinical experience with pegaptanib sodium

Pegaptanib sodium (Macugen((R))) blocks the extracellular vascular endothelial growth factor (VEGF) isoform VEGF(165), whose elevated levels are associated with the development of choroidal neovascularization (CNV). This selective inhibition prevents binding to the VEGF receptors and the development of the increased vascular permeability and the CNV associated with neovascular age-related degen...

Clinical experience with 6-aminonicotinamide.

The toxicity of 6-Aminonicotinamide in 60 patients with advanced malignant disease has been described. The toxicity took two clinical forms: a "deficiency" state with char acteristics of a mixed B-complex vitamin deficiency, and a neurologic disturbance pre sumably due to a direct action on the central nervous system. Individual susceptibility was widely variable. 6-Aminonicotinamide exhibited ...

Pre-clinical experience with daptomycin.

Daptomycin is a broad-spectrum, bactericidal agent active against Gram-positive bacteria, acting largely and unusually through membrane depolarization. Activity is markedly affected in vitro by the availability of calcium ions, and its high molecular weight with associated poor diffusion means that conventional disc diffusion testing is not reliable (and as a consequence not available). In orde...